Posted on 16/12/2009 in Pharmaceutical Company Product News Lilly has been granted Food and Drug Administration (FDA) approval for its adult schizophrenia treatment ZYPREXA RELPREVV (olanzapine).
In a statement, the pharmaceutical organisation explained that the therapy, which is a long-acting intramuscular injection, sustains delivery of olanzapine for a period of up to one month.
Dr John Hayes, vice-president of Lilly Research Laboratories, said that non-adherence to treatment is a more significant barrier to care for people who suffer from schizophrenia than was previously appreciated.
As such, he said that long-acting treatments can play a hugely beneficial role in helping people who suffer from the condition to stick to a stable treatment regimen.
"ZYPREXA RELPREVV provides a new mechanism for helping appropriate patients benefit from the well-characterised efficacy of olanzapine," Dr Hayes concluded.
Earlier this month, Lilly announced that its operations have grown to such an extent that it is now the ninth largest company in terms of global pharmaceutical sales, based on IMS data for the year ended June 2009.Other news stories from 16/12/2009
Read more in the Zenopa News Archive
How this news is generated
|
